Search Results

About a year after cutting staff by 29%, Sana Biotechnology will trim its workforce as it increases investment in its type 1 diabetes program and looks to extend its cash runway.

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors, announced that Dr. Sid Kerkar , the company’s Vice President of Oncology, Research and Development, will participate in the In Vivo Engineering of Therapeutic Cells Summit.

EXUMA Biotech, Corp. presented a poster entitled “In vivo delivery of CD3-directed CD19-CAR lentivectors leads to the generation of CAR T and NK-like (CAR-TaNK) cells capable of complete ablation of B cells in the blood, bone marrow, and tissue of NSG-SGM3 CD34+ humanized mice” and gave an oral presentation in the “25th Anniversary of Trastuzumab: Impact and Future Directions” major symposium at the American Association of Cancer Research Annual Meeting 2023 held in Orlando.

EXUMA Biotech is developing a new modality to produce CAR cells in a single day, with potentially lower toxicity and higher efficacy without the need for preparative chemotherapies.

EXUMA Biotech, Corp. announced that its Chief Business Officer and Head of Finance, Dr. Gregory Wade, will provide a corporate presentation at 11:25 AM ET on Wednesday, September 14, 2022, as part of the annual Baird Global Healthcare Conference in New York.

EXUMA Biotech, Corp. announced that pre-clinical data from its solid-tumor subcutaneous CAR therapy program will be presented at the virtual 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology hosted by the Center of Excellence in Immunology of the National Cancer Institute from September 15 - 16, 2022.

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, today announced the completion of a $41 million Series B2 financing.

Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, announced the acquisition of Serendipity Biosciences, a private biotechnology company focused on the discovery of unique gene editing technologies.